SCHEMBL19928344

SCHEMBL19928344

N#C/C(=C\c1ccccc1)C(N)=S

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.69
ALDH1A1 P00352 9/20 0.69
GAA P10253 3/20 0.69
HTT P42858 1/20 0.69
ATM Q13315 1/20 0.69
MCL1 Q07820 1/20 0.68
TDP1 Q9NUW8 7/20 0.68
KMT2A Q03164 7/20 0.63
KDM4E B2RXH2 7/20 0.63
HPGD P15428 5/20 0.63
MEN1 O00255 6/20 0.60
RECQL P46063 4/20 0.60
BLM P54132 3/20 0.60
NPSR1 Q6W5P4 3/20 0.60
MAPK1 P28482 3/20 0.60
POLB P06746 2/20 0.60
APEX1 P27695 2/20 0.60
PMP22 Q01453 2/20 0.60
RGS12 O14924 2/20 0.60
ERBB2 P04626 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32688162 0.90 MAPT (0.66) MAPTALDH1A1GAAHTTATM
SCHEMBL32688099 0.85 MAPT (0.57) MAPTALDH1A1GAAHTTATM
SCHEMBL32688435 0.81 MAPT (0.70) MAPTALDH1A1GAAHTTATM
SCHEMBL4879813 0.81 MAPT (0.70) MAPTALDH1A1GAAHTTATM
SCHEMBL4878079 0.81 MAPT (0.70) MAPTALDH1A1GAAHTTATM
SCHEMBL4879772 0.81 MAPT (0.70) MAPTALDH1A1GAAHTTATM
SCHEMBL24990617 0.81 MCL1 (0.68) MAPTALDH1A1GAAHTTATM
SCHEMBL1692376 0.81 MCL1 (1.00) MAPTALDH1A1GAAMCL1TDP1
SCHEMBL1692375 0.81 MCL1 (1.00) MAPTALDH1A1GAAMCL1TDP1
SCHEMBL1388543 0.80 MAPT (0.63) MAPTALDH1A1GAAHTTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3883577-B1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY UNIV CASE WESTERN RESERVE (US) 2026-04-08 EP disclosed
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity RODEO THERAPEUTICS CORPORATION (US) 2025-06-24 US disclosed
CN-113507931-B Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2025-05-27 CN disclosed
US-20250161277-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-05-22 US disclosed
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY RODEO THERAPEUTICS CORPORATION 2023-02-09 US disclosed
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY RODEO THERAPEUTICS CORPORATION 2023-02-09 US disclosed
CN-113507931-A Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2021-10-15 CN disclosed
EP-3883577-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2021-09-29 EP disclosed
US-9908893-B2 Thieno [2,3-b] pyridines as multidrug resistance modulators LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2018-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161277-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS MAPT 4066/4885ALDH1A1 126/4885GAA 420/4885
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity HPGD, GCDH, HPGDS MAPT 4066/4885ALDH1A1 126/4885GAA 420/4885
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS MAPT 4066/4885ALDH1A1 126/4885GAA 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.